140 related articles for article (PubMed ID: 34591292)
1. Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
Honda T; Yamaoka M; Terao YM; Hasegawa D; Kumamoto T; Takagi M; Yoshida K; Ogawa S; Goto H; Akiyama M
Int J Hematol; 2022 Jan; 115(1):140-145. PubMed ID: 34591292
[TBL] [Abstract][Full Text] [Related]
2. Hepatosplenic alphabeta T cell lymphoma.
Nagai Y; Ikegame K; Mori M; Inoue D; Kimura T; Shimoji S; Togami K; Tabata S; Kurata M; Imai Y; Matsushita A; Nagai K; Ogawa H; Takahashi T
Int J Clin Oncol; 2010 Apr; 15(2):215-9. PubMed ID: 20217452
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
[TBL] [Abstract][Full Text] [Related]
4. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.
Voss MH; Lunning MA; Maragulia JC; Papadopoulos EB; Goldberg J; Zelenetz AD; Horwitz SM
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):8-14. PubMed ID: 23107915
[TBL] [Abstract][Full Text] [Related]
5. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
Yabe M; Medeiros LJ; Tang G; Wang SA; P Patel K; Routbort M; Bhagat G; Bueso-Ramos CE; Jorgensen JL; Luthra R; Chen W; Muzzafar T; Kanagal-Shamanna R; Khoury JD; Daneshbod Y; Davanlou M; Li S; Young KH; Miranda RN
Hum Pathol; 2016 Apr; 50():109-17. PubMed ID: 26997444
[TBL] [Abstract][Full Text] [Related]
6. Hepatosplenic γδ T-cell lymphoma of two adolescents: Case report and retrospective literature review in children, adolescents, and young adults.
McThenia SS; Rawwas J; Oliveira JL; Khan SP; Rodriguez V
Pediatr Transplant; 2018 Aug; 22(5):e13213. PubMed ID: 29921021
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
[TBL] [Abstract][Full Text] [Related]
8. A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Yu ZP; Ding JH; Sun AN; Chen BA; Ge Z; Wu DP
Stem Cells Dev; 2019 Oct; 28(20):1376-1383. PubMed ID: 31464164
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma.
Sumi M; Takeda W; Kaiume H; Kirihara T; Kurihara T; Sato K; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Kobayashi H
Leuk Lymphoma; 2015 Apr; 56(4):1140-2. PubMed ID: 25065703
[No Abstract] [Full Text] [Related]
10. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
Tang W; Fan X; Wang L; Hu J
Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Krejci M; Doubek M; Brychtova Y; Stehlikova O; Chovancova J; Tichy B; Francova HS; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
Ann Hematol; 2013 Jan; 92(2):249-54. PubMed ID: 23014659
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Yamaguchi M; Kotani T; Nakamura Y; Ueda M
Int J Hematol; 2006 Jun; 83(5):450-3. PubMed ID: 16787878
[TBL] [Abstract][Full Text] [Related]
13. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
[TBL] [Abstract][Full Text] [Related]
14. Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.
Okuni M; Yakushijin K; Uehara K; Ichikawa H; Suto H; Hashimoto A; Tanaka Y; Shinzato I; Sakai R; Mizutani Y; Nagao S; Kurata K; Kakiuchi S; Miyata Y; Inui Y; Saito Y; Kawamoto S; Yamamoto K; Ito M; Matsuoka H; Minami H
Intern Med; 2019 Mar; 58(5):707-712. PubMed ID: 30449784
[TBL] [Abstract][Full Text] [Related]
15. Hepatosplenic T-cell lymphoma presented with massive splenomegaly and pancytopenia - a case report.
Sukrisman L; Rajabto W; Harahap AS; Fanggidae ESDE; Ham MF; Priantono D
Klin Onkol; 2023; 36(3):246-250. PubMed ID: 37353354
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
Yabe M; Medeiros LJ; Tang G; Wang SA; Ahmed S; Nieto Y; Hu S; Bhagat G; Oki Y; Patel KP; Routbort M; Luthra R; Fanale MA; Bueso-Ramos CE; Jorgensen JL; Vega F; Chen W; Hoehn D; Konoplev S; Milton DR; Wistuba I; Li S; You MJ; Young KH; Miranda RN
Am J Surg Pathol; 2016 May; 40(5):676-88. PubMed ID: 26872013
[TBL] [Abstract][Full Text] [Related]
17. Hepatosplenic gamma/delta T-cell lymphoma with isochromosome 7q, translocation t(7;21), and tetrasomy 8 in a 9-year-old girl.
Rossbach HC; Chamizo W; Dumont DP; Barbosa JL; Sutcliffe MJ
J Pediatr Hematol Oncol; 2002 Feb; 24(2):154-7. PubMed ID: 11990705
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
